Price Alert

iTeos Therapeutics Inc. (ITOS)

NASDAQ: ITOS · Real-Time Price · USD

10.11

0.00 (0.00%)

At close: Aug 15, 2025, 3:46 PM

10.11

0.05%

After-hours: Aug 15, 2025, 04:01 PM EDT

iTeos Therapeutics Statistics

Share Statistics

iTeos Therapeutics has 38.27M shares outstanding. The number of shares has increased by 4.8% in one year.

Shares Outstanding	38.27M
Shares Change (YoY)	4.8%
Shares Change (QoQ)	0.21%
Owned by Institutions (%)	78.49%
Shares Floating	41.44M
Failed to Deliver (FTD) Shares	956
FTD / Avg. Volume	0.05%

Short Selling Information

The latest short interest is 3.07M, so 6.95% of the outstanding shares have been sold short.

Short Interest	3.07M
Short % of Shares Out	6.95%
Short % of Float	8.61%
Short Ratio (days to cover)	4.4

Valuation Ratios

The PE ratio is -2.31 and the forward PE ratio is -6.24. iTeos Therapeutics's PEG ratio is -0.43.

PE Ratio	-2.31
Forward PE	-6.24
PS Ratio	8.88
Forward PS	66.2
PB Ratio	0.53
P/FCF Ratio	-3.11
PEG Ratio	-0.43

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for iTeos Therapeutics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 12.62, with a Debt / Equity ratio of 0.01.

Current Ratio	12.62
Quick Ratio	12.62
Debt / Equity	0.01
Debt / EBITDA	-0.03
Debt / FCF	-0.05
Interest Coverage	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$202.31K
Profits Per Employee	$-776.96K
Employee Count	173
Asset Turnover	0.05
Inventory Turnover	n/a

Taxes

Income Tax	14.07M
Effective Tax Rate	-11.69%

Stock Price Statistics

The stock price has increased by -30.28% in the last 52 weeks. The beta is 1.49, so iTeos Therapeutics's price volatility has been higher than the market average.

Beta	1.49
52-Week Price Change	-30.28%
50-Day Moving Average	10.11
200-Day Moving Average	8.2
Relative Strength Index (RSI)	53.41
Average Volume (20 Days)	1,738,766

Income Statement

In the last 12 months, iTeos Therapeutics had revenue of 35M and earned -134.41M in profits. Earnings per share was -3.32.

Revenue	35M
Gross Profit	33.76M
Operating Income	-159.53M
Net Income	-134.41M
EBITDA	-159.53M
EBIT	-154.32M
Earnings Per Share (EPS)	-3.32

Full Income Statement

Balance Sheet

The company has 142.13M in cash and 5.1M in debt, giving a net cash position of 137.03M.

Cash & Cash Equivalents	142.13M
Total Debt	5.1M
Net Cash	137.03M
Retained Earnings	-9.78M
Total Assets	658.87M
Working Capital	499.05M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -98.18M and capital expenditures -1.63M, giving a free cash flow of -99.81M.

Operating Cash Flow	-98.18M
Capital Expenditures	-1.63M
Free Cash Flow	-99.81M
FCF Per Share	-2.47

Full Cash Flow Statement

Margins

Gross margin is 96.46%, with operating and profit margins of -455.79% and -384.04%.

Gross Margin	96.46%
Operating Margin	-455.79%
Pretax Margin	-343.83%
Profit Margin	-384.04%
EBITDA Margin	-455.79%
EBIT Margin	-455.79%
FCF Margin	-285.18%

Dividends & Yields

ITOS does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for ITOS is $11, which is 8.8% higher than the current price. The consensus rating is "Hold".

Price Target	$11
Price Target Difference	8.8%
Analyst Consensus	Hold
Analyst Count	6

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	2.55
Piotroski F-Score	3